로딩 중…
StockDiggingStockDigging

Pfizer Inc.

PFE· NYSE
$27.60-0.14%
2026-09-18

Financials

Valuation Metrics

Pfizer Inc.'s Market Cap is $157.30B. At end of 2025 it was $139.17B. Ranked #100 of 3,121 in US market (top 3%), #64 of 1,658 on NYSE (top 4%), #10 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 4%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$157.30B
Revenue$63.70B
Net Income$4.33B
Total Assets$201.13B
Net Assets$85.19B
Employees75,000
Value
P/E36.29x
P/B1.85x
P/S2.47x
EV/EBITDA17.39x
FCF Yield6.98%
Profitability
ROE5.09%
ROA2.16%
Op. Margin25.08%
Revenue Growth-0.21%
Earnings Growth-59.69%
Financial Health
Debt Ratio135.74%
Total Debt$63.19B
FCF$10.99B
Cash$976M
Current Ratio1.27x
Net Debt/EBITDA4.93x
Dividend
Div. Yield6.22%
Div. Growth2.38%
Performance
1Y Return18.25%
1M Return-2.27%
From 52W High-5.51%
1Y MDD-17.09%
Trading
Volume23,905,475 shares
Trading Value$658M
Per Share
EPS$0.76
BPS$14.95

Company Info

CEO Dr. Albert Bourla D.V.M., Ph.D.
Employees 75,000
HQ New York, United States

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.